Short answer
Regeneron Pharmaceuticals (REGN) filed an 8-K current report with the SEC on June 17, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All five Class II director nominees elected through 2027; David Schenkein and Huda Zoghbi received strongest support.
Regeneron Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All five Class II director nominees elected through 2027; David Schenkein and Huda Zoghbi received strongest support
- Joseph Goldstein faced highest opposition, with 30,904,254 votes against, signaling notable shareholder concern
- PwC appointment ratified for fiscal 2026, maintaining auditor continuity
- Executive compensation approved on an advisory basis, with 96,469,374 votes for and 6,898,268 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Regeneron Pharmaceuticals 8-K filings
Get the next REGN 8-K as it lands
Follow REGN for push alerts, or ask the research agent what this filing means.